Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180477 | 0.97 | — | — | |
| SCHEMBL4212994 | 0.94 | GLRA1 (0.33) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL4202756 | 0.94 | GLRA1 (0.33) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL288431 | 0.85 | — | — | |
| SCHEMBL6753492 | 0.82 | GLRA1 (0.41) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| Hydrogen Peroxide SCHEMBL4370693 | 0.82 | GLRA1 (0.50) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL6258848 | 0.82 | GLRA1 (0.41) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL10794891 | 0.82 | GLRA1 (0.41) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL27360124 | 0.82 | GLRA1 (0.41) | GLRA1SLC6A9OR51E2ALDH1A1KDM4E | |
| SCHEMBL132924 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209642-A1 | Hydroxy Acid Complexes for Antiaging and Skin Renovation | BIODERM RESEARCH (US) | 2009-08-20 | — | — | US | claimed |
| US-7547454-B2 | Hydroxy acid complexes for antiaging and skin renovation | GUPTA SHYAM K | 2009-06-16 | — | — | US | claimed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209642-A1 | Hydroxy Acid Complexes for Antiaging and Skin Renovation | CUTA, SLC30A6, SLC30A7 | GLRA1 2414/4885SLC6A9 2529/4885OR51E2 3527/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | GLRA1 2980/4885SLC6A9 4603/4885OR51E2 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.